Safety and Efficacy of Nitric Oxide Gel in Promoting Hair Growth in Male Human Subjects With Androgenetic Alopecia
The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2013 by China Medical University Hospital.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
China Medical University Hospital
Information provided by (Responsible Party):
China Medical University Hospital
ClinicalTrials.gov Identifier:
NCT01347957
First received: May 3, 2011
Last updated: February 12, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Preclinical studies showed the Nitric Oxide (NO) gel significantly promoted hair follicle formation and growth in both rat and mouse models. The NO gel induced major physiological, developmental, and structural changes in the skin of mammals to increase the number of hair follicles, follicle stem cell development and regeneration as well as hair shaft elongation, and accelerated hair growth rate. Based on our animal model findings, the investigators hypothesize that the nitric oxide releasing gel could be used as a medical treatment for hair growth in humans. The objective of this trial is to evaluate the safety and efficacy of this NO gel (XN-001), in comparison with a placebo gel in subjects in a 24-week treatment schedule.
| Condition | Intervention | Phase |
|---|---|---|
|
Alopecia Androgenica |
Other: Nitric Oxide (NO) Gel Other: Placebo gel |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
Resource links provided by NLM:
Genetics Home Reference related topics:
androgenetic alopecia
Drug Information available for:
Nitric oxide
U.S. FDA Resources
Further study details as provided by China Medical University Hospital:
Primary Outcome Measures:
- The primary efficacy endpoint is the difference in TAHC between baseline and after 24-week treatment (NO vs. placebo groups). [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- The secondary efficacy end point will be subjective assessment of improvement. [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
Subjects will be instructed to fill out a questionnaire at week 24 to evaluate the overall condition of hair loss in comparison with baseline.
Subjects will be evaluated for any possible adverse effects of study drug and any symptoms and signs of scalp irritation (stinging, burning, itching)
| Estimated Enrollment: | 60 |
| Study Start Date: | August 2012 |
| Estimated Study Completion Date: | August 2013 |
| Estimated Primary Completion Date: | August 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Nitric Oxide (NO) Gel |
Other: Nitric Oxide (NO) Gel
Nitric Oxide (NO) Gel is created by premixing of contents from 2 separate gel bottles. The first bottle, NO gel, is a solution of sodium nitrite (14.6mM) in distilled water with hydroxyethylcellulose (molecular weight 50,000-1,250,000) added for gel formation. The second bottle, Releasing-stimulator gel, is a solution of maleic acid (14.6mM) and ascorbic acid (14.6mM) in distilled water with hydroxyethylcellulose added for gel formation.
|
| Placebo Comparator: Placebo Gel |
Other: Placebo gel
The placebo gel is created by premixing of contents from 2 separate gel bottles. The first bottle is phosphate-buffered saline. The second bottle is the second gel bottle (Releasing-stimulator gel) as described in experimental arm.
|
Eligibility| Ages Eligible for Study: | 20 Years to 65 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Male subjects >= 20 and <= 65 years of age.
- Subjects with hair loss caused by androgenetic alopecia.
- Subjects who are healthy without any serious diseases that require hospitalization during the study period.
- Subjects who are capable of understanding and having signed the Informed Consent Form after detailed description of the treatment procedures and potential risks and benefits.
Exclusion Criteria:
- Subjects who received any treatment for hair loss within 6 months or finasteride within 12 months
- Subjects with diagnosis of cancer and is still on active therapies.
- Subjects with diagnosis of an active disease and is still under regular treatment for this disease
- Subjects with hair loss caused by a known chronic disease.
- Subjects who are on vasodilators or other medication with pharmacological actions that may lead to excessive formation of nitric oxide or may accentuate drug effects due to excessive formation of nitric oxide.
- Subjects with thyroid disease.
- Subjects iron-deficiency anemia.
- Subjects with skin diseases of the scalp, including severe seborrhoeic dermatitis, psoriasis, lichenoid eruption, tinea capitis, or other scalp infections or infestations
- Subjects with any known allergic reaction to any ingredient in the 2 gel preparations.
- Subjects who have been enrolled into any clinical study in the preceding 6 months prior to randomization.
- Subjects who have taken medications that are known to induce hypotrichosis or hypertrichosis.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01347957
Please refer to this study by its ClinicalTrials.gov identifier: NCT01347957
Contacts
| Contact: CHIH JUNG HSU | 0953661694 |
Locations
| Taiwan | |
| Dermatological Department, CMUH | Recruiting |
| Taichung, Taiwan | |
Sponsors and Collaborators
China Medical University Hospital
Investigators
| Principal Investigator: | Chih JUNG HSU | Dermatological department, CMUH |
More Information
No publications provided
| Responsible Party: | China Medical University Hospital |
| ClinicalTrials.gov Identifier: | NCT01347957 History of Changes |
| Other Study ID Numbers: | DMR98-IRB-231 |
| Study First Received: | May 3, 2011 |
| Last Updated: | February 12, 2013 |
| Health Authority: | Taiwan: Institutional Review Board |
Additional relevant MeSH terms:
|
Nitric Oxide Anti-Asthmatic Agents Antioxidants Autonomic Agents Bronchodilator Agents Cardiovascular Agents Endothelium-Dependent Relaxing Factors Free Radical Scavengers Gasotransmitters |
Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Peripheral Nervous System Agents Pharmacologic Actions Physiological Effects of Drugs Protective Agents Respiratory System Agents Therapeutic Uses Vasodilator Agents |
ClinicalTrials.gov processed this record on March 01, 2015